MXPA04002379A - Compuestos novedosos. - Google Patents

Compuestos novedosos.

Info

Publication number
MXPA04002379A
MXPA04002379A MXPA04002379A MXPA04002379A MXPA04002379A MX PA04002379 A MXPA04002379 A MX PA04002379A MX PA04002379 A MXPA04002379 A MX PA04002379A MX PA04002379 A MXPA04002379 A MX PA04002379A MX PA04002379 A MXPA04002379 A MX PA04002379A
Authority
MX
Mexico
Prior art keywords
pain
treatment
urea
vanilloid receptor
receptor antagonists
Prior art date
Application number
MXPA04002379A
Other languages
English (en)
Inventor
Thompson Mervyn
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0122156A external-priority patent/GB0122156D0/en
Priority claimed from GB0130505A external-priority patent/GB0130505D0/en
Priority claimed from GB0130503A external-priority patent/GB0130503D0/en
Priority claimed from GB0130547A external-priority patent/GB0130547D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of MXPA04002379A publication Critical patent/MXPA04002379A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se describen algunos compuestos de formula (l), (ver formula) o una sal o solvato farmaceuticamente aceptable de los mismos, en donde R1, R2, P, P1, n, p, q, r y s son como se define en la especificacion; un procedimiento para preparar dichos compuestos; una composicion farmaceutica que comprende dichos compuestos; y el uso de dichos compuestos y composicion en medicina.
MXPA04002379A 2001-09-13 2002-09-13 Compuestos novedosos. MXPA04002379A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0122156A GB0122156D0 (en) 2001-09-13 2001-09-13 Novel compounds
GB0130505A GB0130505D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130503A GB0130503D0 (en) 2001-12-20 2001-12-20 Novel compounds
GB0130547A GB0130547D0 (en) 2001-12-20 2001-12-20 Novel compounds
PCT/GB2002/004206 WO2003022809A2 (en) 2001-09-13 2002-09-13 Urea-compounds active as vanilloid receptor antagonists for the treatment of pain

Publications (1)

Publication Number Publication Date
MXPA04002379A true MXPA04002379A (es) 2004-05-31

Family

ID=27447989

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002379A MXPA04002379A (es) 2001-09-13 2002-09-13 Compuestos novedosos.

Country Status (32)

Country Link
US (1) US8063078B2 (es)
EP (3) EP2036902A3 (es)
JP (2) JP4463552B2 (es)
KR (3) KR100955967B1 (es)
CN (1) CN1247568C (es)
AP (1) AP1818A (es)
AR (1) AR038786A1 (es)
AT (1) ATE420083T1 (es)
AU (1) AU2002329397B2 (es)
BR (1) BR0212468A (es)
CA (1) CA2458632C (es)
CY (1) CY1109449T1 (es)
DE (1) DE60230773D1 (es)
DK (1) DK1425277T3 (es)
EA (1) EA007731B1 (es)
ES (1) ES2316607T3 (es)
HK (1) HK1066534A1 (es)
HU (1) HUP0401923A3 (es)
IL (2) IL160755A0 (es)
MA (1) MA26216A1 (es)
MX (1) MXPA04002379A (es)
MY (1) MY138086A (es)
NO (3) NO327009B1 (es)
NZ (1) NZ531137A (es)
OA (1) OA12659A (es)
PE (1) PE20030417A1 (es)
PL (1) PL213639B1 (es)
PT (1) PT1425277E (es)
SI (1) SI1425277T1 (es)
TW (1) TWI283665B (es)
UY (1) UY27446A1 (es)
WO (1) WO2003022809A2 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
AU2003212882A1 (en) 2002-02-01 2003-09-02 Euro-Celtique S.A. 2 - piperazine - pyridines useful for treating pain
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
MXPA04008073A (es) * 2002-02-20 2004-11-26 Abbott Lab Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide.
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
DK1556354T3 (da) 2002-06-28 2008-06-02 Euro Celtique Sa Terapeutiske piperazinderivater, der er egnede til behandling af smerter
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
GB0221157D0 (en) * 2002-09-12 2002-10-23 Glaxo Group Ltd Novel treatment
AU2003270199A1 (en) * 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
DE60315704T2 (de) 2002-12-06 2008-06-05 Xention Ltd. Iconix Park Tetrahydronaphalin-derivate
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
WO2004078749A1 (en) * 2003-03-06 2004-09-16 Glaxo Group Limited Heterocyclic urea derivatives for the treatment of pain
WO2004078744A2 (en) * 2003-03-07 2004-09-16 Glaxo Group Limited Urea derivatives and their use as vanilloid receptor antagonists in the treatment of pain
GB0305426D0 (en) * 2003-03-08 2003-04-16 Glaxo Group Ltd Novel compounds
SE0301446D0 (sv) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
ATE556067T1 (de) 2003-05-20 2012-05-15 Ajinomoto Kk Modulatoren des vanilloid rezeptors
EP1493438A1 (en) * 2003-07-03 2005-01-05 Bayer HealthCare AG Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states
GB0319150D0 (en) 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
JP4833069B2 (ja) * 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
JP4935073B2 (ja) 2003-10-14 2012-05-23 味の素株式会社 エーテル誘導体
US20080045546A1 (en) * 2003-10-15 2008-02-21 Axel Bouchon Tetradydro-Naphthalene And Urea Derivatives
JP2007523888A (ja) 2003-11-08 2007-08-23 バイエル・ヘルスケア・アクチェンゲゼルシャフト テトラヒドロ−キノリニル尿素誘導体
EP1736465A4 (en) 2004-03-31 2009-06-17 Ajinomoto Kk ANILINE DERIVATIVES
EP1768954A4 (en) 2004-06-24 2008-05-28 Incyte Corp 2-METHYLPROPANAMIDES AND THEIR USE AS PHARMACEUTICALS
US7879866B2 (en) 2004-07-19 2011-02-01 Dorte Xenia Gram Inhibition of the activity of the capsaicin receptor in the treatment of obesity or obesity-related diseases and disorders
KR20060087386A (ko) 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
WO2006098554A1 (en) * 2005-03-16 2006-09-21 Amorepacific Corporation Novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and a pharmaceutical composition containing the same
WO2007046867A2 (en) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
AR058705A1 (es) 2005-12-23 2008-02-20 Astrazeneca Ab Compuestos de bencimidazol como inhibidores del receptor vaniloide 1 (vr1)
EP1889830A1 (en) * 2006-07-10 2008-02-20 Pharmeste S.r.l. Biarylcarboxyarylamides as vanilloid-1 receptor modulators
EP2054411B1 (en) * 2006-07-27 2014-08-20 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
TWI433839B (zh) 2006-08-11 2014-04-11 Neomed Inst 新穎的苯并咪唑衍生物290
CA2661898A1 (en) 2006-08-25 2008-02-28 Abbott Laboratories Indazole derivatives that inhibit trpv1 and uses thereof
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
EP2323989A4 (en) 2008-03-20 2011-06-22 Abbott Lab METHODS FOR PREPARING AGENTS FOR THE CENTRAL NERVOUS SYSTEM THAT ARE TRPV1 ANTAGONISTS
CN101983197B (zh) 2008-04-18 2015-04-22 大熊制药株式会社 新型苯并噁嗪苯并咪唑衍生物、含有该衍生物的药物组合物及其用途
KR101409651B1 (ko) * 2008-05-07 2014-06-18 다이닛본 스미토모 세이야꾸 가부시끼가이샤 시클릭 아민-1-카르복실산 에스테르 유도체 및 그것을 함유하는 약제학적 조성물
WO2010026129A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited The trpvl antagonist sb-705498 for treating rhinitis
WO2010026128A1 (en) * 2008-09-02 2010-03-11 Glaxo Group Limited N-(3-methyl-5-isoquinolinyl)-n'-((3r)-1-[5-(trifluoromethyl)-2-pyridinyl]-3-pyrrolidinyl) urea for the treatment of rhinitis
JP2013028536A (ja) * 2009-11-11 2013-02-07 Dainippon Sumitomo Pharma Co Ltd 環状アミン−１−カルボン酸エステル誘導体およびそれを含有する医薬組成物
WO2012045729A1 (en) 2010-10-05 2012-04-12 Glaxo Group Limited Imidazo [1, 2 -a] pyridine and pyrazolo [1, 5 -a] pyridine derivatives as trpv1 antagonists
KR101293384B1 (ko) 2010-10-13 2013-08-05 주식회사 대웅제약 신규 피리딜 벤조옥사진 유도체, 이를 포함하는 약학 조성물 및 이의 용도
WO2012072512A1 (en) 2010-11-29 2012-06-07 Glaxo Group Limited N-cyclobutyl-imidazopyridine or -pyrazolopyridine carboxamides as trpv1 antagonists
GB201101517D0 (en) * 2011-01-28 2011-03-16 Proximagen Ltd Receptor antagonists
JP2014510768A (ja) 2011-04-11 2014-05-01 グラクソ グループ リミテッド Ｔｒｐｖ１アンタゴニストとしてのｎ−シクロブチルイミダゾピリジンメチルアミン
DE102022104759A1 (de) 2022-02-28 2023-08-31 SCi Kontor GmbH Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3424761A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
US3424760A (en) * 1966-03-07 1969-01-28 Robins Co Inc A H 3-ureidopyrrolidines
GB1460389A (en) * 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants
ATE113205T1 (de) 1988-06-17 1994-11-15 Procter & Gamble Anwendung von vanillin-derivaten zur herstellung eines arzneimittels zur behandlung von herpes simplex-infektion.
HU206082B (en) 1988-12-23 1992-08-28 Sandoz Ag Process for producing capsaicin derivatives and pharmaceutical compositions comprising such compounds
CA2017383A1 (en) 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
WO1992009285A1 (en) 1990-11-27 1992-06-11 The Procter & Gamble Company Combinations of vanilloid compounds and phosphonate antiviral compounds for treatment of herpes infections
US5149704A (en) 1991-05-03 1992-09-22 Abbott Laboratories Platelet activating antagonists
CA2197364A1 (en) * 1996-02-15 1997-08-16 Toshikazu Suzuki Phenol compound and process for preparing the same
DE69830504T2 (de) * 1997-06-26 2006-03-16 Eli Lilly And Co., Indianapolis Antithrombotische mitteln
US6313122B1 (en) * 1997-06-26 2001-11-06 Eli Lilly And Company Antithrombotic agents
JP2000080085A (ja) 1997-09-01 2000-03-21 Kyorin Pharmaceut Co Ltd ６，７−非対称ジ置換キノキサリンカルボン酸誘導体とその付加塩及びそれらの製造方法
CN1210254C (zh) 1999-02-22 2005-07-13 株式会社太平洋 作为有效的香草类受体激动剂和镇痛药的含有树脂毒素药效基团的香草类类似物,其组合物以及应用
EP1165516B1 (en) 1999-03-12 2004-10-06 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic urea and related compounds useful as anti-inflammatory agents
US6608227B1 (en) * 1999-10-15 2003-08-19 Bristol-Myers Squibb Pharma Benzylcycloalkyl amines as modulators of chemokine receptor activity
EP1301484A2 (en) 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin receptor ligands
ATE328868T1 (de) 2000-08-21 2006-06-15 Pacific Corp Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten
WO2002016317A1 (en) 2000-08-21 2002-02-28 Pacific Corporation Novel thiocarbamic acid derivatives and the pharmaceutical compositions containing the same
ATE393141T1 (de) 2000-08-21 2008-05-15 Pacific Corp Neue thiourea-derivate und pharmazeutische zusammensetzungen die diese enthalten
JP2002080073A (ja) 2000-09-07 2002-03-19 Kyokuto Kobunshi Kk 電子レンジ用自動開孔袋
JP2002088073A (ja) * 2000-09-08 2002-03-27 Yamanouchi Pharmaceut Co Ltd 抗アンドロゲン剤
GB0110901D0 (en) 2001-05-02 2001-06-27 Smithkline Beecham Plc Novel Compounds
PE20030417A1 (es) * 2001-09-13 2003-08-06 Smithkline Beecham Plc Derivados de urea como antagonistas del receptor vainilloide
MXPA05000081A (es) * 2002-06-27 2005-04-11 Schering Ag Quinolinas sustituidas antagonistas del receptor ccr5.
AU2003270199A1 (en) * 2002-09-13 2004-04-30 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229808D0 (en) 2002-12-20 2003-01-29 Glaxo Group Ltd Novel compositions
WO2005103018A1 (en) 2004-04-20 2005-11-03 Bayer Healthcare Ag Urea derivatives as antagonists of the vanilloid receptor (vr1)

Also Published As

Publication number Publication date
JP4463552B2 (ja) 2010-05-19
HUP0401923A3 (en) 2012-09-28
CY1109449T1 (el) 2014-08-13
JP2010100632A (ja) 2010-05-06
EP2036902A2 (en) 2009-03-18
KR20090026369A (ko) 2009-03-12
TWI283665B (en) 2007-07-11
NZ531137A (en) 2006-08-31
PL213639B1 (pl) 2013-04-30
AP2004002982A0 (en) 2004-03-31
MY138086A (en) 2009-04-30
CA2458632A1 (en) 2003-03-20
PE20030417A1 (es) 2003-08-06
MA26216A1 (fr) 2004-07-01
HK1066534A1 (en) 2005-03-24
KR100955967B1 (ko) 2010-05-04
HUP0401923A2 (hu) 2005-01-28
EP2298757A3 (en) 2011-12-28
KR101063679B1 (ko) 2011-09-07
PT1425277E (pt) 2009-03-05
US20090163506A1 (en) 2009-06-25
EP1425277B1 (en) 2009-01-07
NO20085078L (no) 2004-06-04
WO2003022809A2 (en) 2003-03-20
IL160755A (en) 2009-09-01
PL369026A1 (en) 2005-04-18
OA12659A (en) 2006-06-19
NO327009B1 (no) 2009-04-06
UY27446A1 (es) 2003-04-30
AP1818A (en) 2008-01-07
EA200400432A1 (ru) 2004-12-30
EP2298757A2 (en) 2011-03-23
ATE420083T1 (de) 2009-01-15
CA2458632C (en) 2011-08-23
EP1425277B8 (en) 2009-04-01
DK1425277T3 (da) 2009-03-16
EP2036902A3 (en) 2009-05-06
BR0212468A (pt) 2004-10-19
IL160755A0 (en) 2004-08-31
NO20041003L (no) 2004-06-04
AU2002329397B2 (en) 2006-04-27
KR20040041610A (ko) 2004-05-17
ES2316607T3 (es) 2009-04-16
US8063078B2 (en) 2011-11-22
SI1425277T1 (sl) 2009-04-30
WO2003022809A3 (en) 2003-07-17
CN1247568C (zh) 2006-03-29
JP2005504074A (ja) 2005-02-10
NO20085077L (no) 2004-06-04
DE60230773D1 (de) 2009-02-26
EA007731B1 (ru) 2006-12-29
EP1425277A2 (en) 2004-06-09
AR038786A1 (es) 2005-01-26
KR20100082390A (ko) 2010-07-16
CN1553905A (zh) 2004-12-08

Similar Documents

Publication Publication Date Title
MXPA04002379A (es) Compuestos novedosos.
NZ522326A (en) Adenosine A2A receptor antagonists
TW200745111A (en) New compounds
EP0709376A3 (en) Therapeutic compounds
MY137535A (en) New pyrrolidinium derivatives
CA2503900A1 (en) Purine compounds and use thereof as cannabinoid receptor ligands
TW200606164A (en) New compounds
SE0100568D0 (sv) Compounds
ID26128A (id) Senyawa-senyawa aminotetralin tersubstitusi-n sebagai ligan-ligan untuk reseptor neupeptida y y5 yang bermanfaat dalam pengobatan obesitas dan gangguan-gangguan lain
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
DE602004011394D1 (en) Thiazolderivate
WO2003048164A3 (en) Adenosine a2a receptor antagonists
CA2468649A1 (en) Adenosine a2a receptor antagonists
WO2005056524A3 (en) Therapeutic agents useful for treating pain
DE602004023946D1 (de) Kombinationen aus einem arylanilin-beta-2-adrenozeptor-agonisten und einem corticosteroid
IL187591A0 (en) Pharmaceutical composition as solid dosage from and method for manufacturing thereof
WO2002065979A3 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
TW200800984A (en) New compounds
GB0109122D0 (en) Novel compounds
SE0104331D0 (sv) Novel compounds
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
SE0102440D0 (sv) New compound
AP2002002697A0 (en) Biciclic cyclohexylamines and their use as NMDA receptor antagonists.
SE0100566D0 (sv) Compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy

Legal Events

Date Code Title Description
FG Grant or registration